Wednesday, July 10, 2013

Roche stops diabetes drug trial after safety issues

Related News

  • Idenix sees delay in human trials for hep C drug as FDA seeks more data

    Thu, Jun 20 2013

  • Lilly halts Alzheimer's drug trial due to liver problems

    Thu, Jun 13 2013

A logo of Swiss pharmaceutical company Roche is pictured at a company's building in Rotkreuz, April 12, 2012. REUTERS/Michael Buholzer

A logo of Swiss pharmaceutical company Roche is pictured at a company's building in Rotkreuz, April 12, 2012.

Credit: Reuters/Michael Buholzer

ZURICH | Wed Jul 10, 2013 1:17am EDT

ZURICH (Reuters) - Roche said it would stop developing aleglitazar, a diabetes treatment, due to safety reasons and lack of effectiveness.

"Roche is working with investigators to support the management of patients and their transition from aleglitazar treatment to other blood sugar control therapies," Roche's chief medical offer and head of product development Hal Barron said in a statement on Wednesday.

The undisclosed safety questions were uncovered by a safety review conducted by an independent group of drug experts during a late-stage trial.

(Reporting By Katharina Bart)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


Source : http://feeds.reuters.com/~r/reuters/healthNews/~3/8iS3FOu2ddY/story01.htm

Posted by at